TERAVOLT: Thoracic cancers indicate an unexpectedly high mortality rate in patients with COVID-19

Share :
Published: 21 May 2020
Views: 912
Dr Heather Wakelee - Stanford University Medical Center, Stanford, USA

Dr Heather Wakelee from Stanford University speaks to ecancer about the TERAVOLT study.

The TERAVOLT registry was launched in March with the aim of gathering information on patients with thoracic cancer infected with COVID-19 regardless of therapies administered.

She discusses the reasoning behind TERAVOLT which started in Milan during the COVID outbreak.

Dr Wakelee goes through some of the initial results from the study, which Prof Garassino presented at the AACR 2020 virtual meeting, which covered 200 patients' data within a month.